What is Leerink Partnrs’ Estimate for VRDN FY2029 Earnings?

Viridian Therapeutics, Inc. (NASDAQ:VRDN) – Stock analysts at Leerink Partnrs issued their FY2029 EPS estimates for Viridian Therapeutics in a research report issued to clients and investors on Monday, January 27th. Leerink Partnrs analyst T. Smith expects that the company will post earnings of $3.00 per share for the year. The consensus estimate for Viridian Therapeutics’ current full-year earnings is ($4.03) per share.

Viridian Therapeutics (NASDAQ:VRDN) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($1.15) EPS for the quarter, missing the consensus estimate of ($1.11) by ($0.04). Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. The company had revenue of $0.09 million during the quarter, compared to the consensus estimate of $0.08 million.

A number of other research firms have also recently commented on VRDN. Wells Fargo & Company reissued an “equal weight” rating and set a $27.00 target price (down previously from $37.00) on shares of Viridian Therapeutics in a research report on Thursday, December 19th. HC Wainwright restated a “buy” rating and set a $34.00 target price on shares of Viridian Therapeutics in a research note on Monday, December 16th. TD Cowen assumed coverage on Viridian Therapeutics in a research note on Monday, November 25th. They issued a “buy” rating for the company. Needham & Company LLC restated a “buy” rating and set a $38.00 price target on shares of Viridian Therapeutics in a research note on Tuesday, January 7th. Finally, Royal Bank of Canada increased their price objective on shares of Viridian Therapeutics from $44.00 to $47.00 and gave the company an “outperform” rating in a research report on Tuesday, December 17th. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $35.70.

Viridian Therapeutics Stock Performance

VRDN stock opened at $19.21 on Tuesday. The firm has a 50-day simple moving average of $19.43 and a two-hundred day simple moving average of $19.39. The company has a debt-to-equity ratio of 0.04, a quick ratio of 18.55 and a current ratio of 18.55. Viridian Therapeutics has a one year low of $11.40 and a one year high of $27.20. The firm has a market cap of $1.52 billion, a price-to-earnings ratio of -4.46 and a beta of 1.13.

Hedge Funds Weigh In On Viridian Therapeutics

A number of hedge funds have recently made changes to their positions in VRDN. FMR LLC boosted its stake in Viridian Therapeutics by 16.8% during the 3rd quarter. FMR LLC now owns 11,183,478 shares of the company’s stock worth $254,424,000 after purchasing an additional 1,610,130 shares during the last quarter. Novo Holdings A S boosted its position in Viridian Therapeutics by 19.3% during the third quarter. Novo Holdings A S now owns 2,385,000 shares of the company’s stock worth $54,259,000 after acquiring an additional 385,000 shares during the last quarter. Geode Capital Management LLC grew its stake in Viridian Therapeutics by 5.8% during the 3rd quarter. Geode Capital Management LLC now owns 1,493,311 shares of the company’s stock valued at $33,979,000 after acquiring an additional 81,951 shares in the last quarter. Great Point Partners LLC raised its holdings in Viridian Therapeutics by 50.0% in the 3rd quarter. Great Point Partners LLC now owns 750,000 shares of the company’s stock valued at $17,062,000 after acquiring an additional 250,000 shares during the last quarter. Finally, Walleye Capital LLC lifted its stake in Viridian Therapeutics by 30.1% in the 3rd quarter. Walleye Capital LLC now owns 560,007 shares of the company’s stock worth $12,740,000 after purchasing an additional 129,411 shares in the last quarter.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.